Search

Displaying results 2581 - 2590 of 2955 in total
  1. Drug

    Rimacalib

    go.drugbank.com/drugs/DB12571
    Investigational

    Rimacalib has been used in trials studying the treatment of Rheumatoid Arthritis (RA).

  2. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A. … [A230088] Fosdenopterin was approved by the FDA on Februrary 26, 2021, for the reduction of mortality in patients with MoCD type A,[L32163] becoming the first and only therapy approved for the treatment

  3. Drug

    Evolocumab

    go.drugbank.com/drugs/DB09303
    ApprovedInvestigational

    It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering.

  4. Drug

    Diroximel fumarate

    go.drugbank.com/drugs/DB14783
    ApprovedInvestigational

    Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019[L9626] and by the EMA in November 2021.[L39225]

  5. Drug

    Moxetumomab pasudotox

    go.drugbank.com/drugs/DB12688
    ApprovedInvestigational

    [A38864] It was developed by Astra Zeneca and FDA approved on September 13, 2018, after being granted the status of Fast Track, Priority Review and Orphan Drug designations.[L4568]

  6. Drug

    Glatiramer

    go.drugbank.com/drugs/DB05259
    ApprovedInvestigational

    [A248880] It was approved by the FDA in 1996, and a generic version became available in 2017.

  7. Drug

    Efbemalenograstim alfa

    go.drugbank.com/drugs/DB18704
    ApprovedInvestigational

    [A33650,A262172] On November 22, 2023, efbemalenograstim alfa was approved by the FDA under the brand name Ryzneuta for the treatment of chemotherapy-induced neutropenia in adult patients with non-myeloid

  8. Drug

    mRNA-1283

    go.drugbank.com/drugs/DB22668
    ApprovedInvestigational

    [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from

  9. Drug

    Tebipenem pivoxil

    go.drugbank.com/drugs/DB16840
    Approved

    [L57979] The FDA approved tebipenem pivoxil on June 17, 2026, for complicated urinary tract infections including pyelonephritis caused by designated susceptible organisms in adult patients who have

  10. Drug

    Ioversol

    go.drugbank.com/drugs/DB09134
    ApprovedInvestigational

    [L41780] Ioversol was approved by the FDA in 1989 and is currently indicated for computed tomographic (CT) imaging and contrast enhancement in peripheral arteriography, coronary arteriography, and left